Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis ...

Despite advancements in prenatal genetic screening, current medical technology cannot identify all genetic conditions in ...

Fexlamose is being developed as a chronic treatment for COPD and asthma in conjunction with standard therapies, to improve ...

Sophie Pierce is determined to make the most of her life - however long she may have.

Detailed price information for Vertex Pharmaceutic (VRTX-Q) from The Globe and Mail including charting and trades.

We recently compiled a list of the 12 Best Multibagger Stocks to Buy Right Now. In this article, we are going to take a look ...

In this article, we will discuss the 12 Best Multibagger Stocks to Buy Right Now. The US equities continued their upward movement in 2024 and fueled the S&P 500 to record highs. Much of this optimism ...

Second Phase 3 Clinical ... in patients with cystic fibrosis ... Nov. 23, 2022 — Sometimes healthcare professionals treat patients with opioids such as morphine to relieve symptoms, but there ...

Arcturus Therapeutics initiates patient dosing in phase 2 multiple ascending dose studies for CF and OTC deficiency: San Diego Wednesday, January 8, 2025, 13:00 Hrs [IST] Arcturus ...

AIM To determine how early diagnosis of cystic fibrosis, using neonatal screening, affects long term clinical outcome ... respectively. As expected, symptoms were present at diagnosis in a ...

Introduction Cystic ... in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, primarily affecting the respiratory and digestive systems. Respiratory rehabilitation techniques play a ...